CR20180350A - Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer - Google Patents
Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncerInfo
- Publication number
- CR20180350A CR20180350A CR20180350A CR20180350A CR20180350A CR 20180350 A CR20180350 A CR 20180350A CR 20180350 A CR20180350 A CR 20180350A CR 20180350 A CR20180350 A CR 20180350A CR 20180350 A CR20180350 A CR 20180350A
- Authority
- CR
- Costa Rica
- Prior art keywords
- domain
- mfa
- alfa
- vaccination
- cancer treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263377P | 2015-12-04 | 2015-12-04 | |
| US201662422454P | 2016-11-15 | 2016-11-15 | |
| PCT/US2016/064969 WO2017096374A1 (en) | 2015-12-04 | 2016-12-05 | Vaccination with mica/b alpha 3 domain for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20180350A true CR20180350A (es) | 2018-10-02 |
Family
ID=57590885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20180350A CR20180350A (es) | 2015-12-04 | 2016-12-05 | Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer |
| CR20230116A CR20230116A (es) | 2015-12-04 | 2016-12-05 | Composición de vacuna que comprende el dominio alfa 3 de mica/b (div. 2018-350) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230116A CR20230116A (es) | 2015-12-04 | 2016-12-05 | Composición de vacuna que comprende el dominio alfa 3 de mica/b (div. 2018-350) |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10993971B2 (enExample) |
| EP (1) | EP3383426A1 (enExample) |
| JP (3) | JP7099956B2 (enExample) |
| KR (1) | KR20180088458A (enExample) |
| CN (1) | CN108770343A (enExample) |
| AU (3) | AU2016362597C1 (enExample) |
| BR (1) | BR112018010705A8 (enExample) |
| CA (1) | CA3005910A1 (enExample) |
| CL (3) | CL2018001470A1 (enExample) |
| CO (1) | CO2018006642A2 (enExample) |
| CR (2) | CR20180350A (enExample) |
| CU (2) | CU20210061A7 (enExample) |
| EA (1) | EA201891287A1 (enExample) |
| IL (1) | IL259490A (enExample) |
| MX (2) | MX2018006785A (enExample) |
| MY (1) | MY199248A (enExample) |
| NZ (1) | NZ742663A (enExample) |
| PE (2) | PE20230495A1 (enExample) |
| PH (1) | PH12018501170A1 (enExample) |
| RU (2) | RU2747296C2 (enExample) |
| SG (1) | SG11201804597TA (enExample) |
| TN (1) | TN2018000187A1 (enExample) |
| WO (1) | WO2017096374A1 (enExample) |
| ZA (1) | ZA202204223B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210018205A (ko) | 2018-04-03 | 2021-02-17 | 사노피 | 항원성 OspA 폴리펩타이드 |
| EP3773708A2 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Antigenic epstein barr virus polypeptides |
| MX2020010199A (es) | 2018-04-03 | 2021-01-08 | Sanofi Sa | Polipeptidos antigenicos del virus sincitial respiratorio. |
| EP3773698A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Ferritin proteins |
| KR102594083B1 (ko) | 2020-07-07 | 2023-10-25 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
| CN116396398B (zh) * | 2023-01-16 | 2024-07-16 | 四川大学 | 一种实现铁蛋白纳米颗粒可控自组装的方法以及基于该方法搭建的纳米颗粒抗原展示平台 |
| WO2024222886A1 (zh) * | 2023-04-28 | 2024-10-31 | 北京先声祥瑞生物制品股份有限公司 | 一种针对MICA/B靶点的mRNA肿瘤疫苗 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
| US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| ES2055785T3 (es) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. |
| KR920703114A (ko) | 1989-07-14 | 1992-12-17 | 원본미기재 | 접합체 백신을 위한 시토킨 및 호르몬 운반체 |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| ATE128628T1 (de) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff. |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| CA2135052A1 (en) | 1992-05-06 | 1993-11-11 | R. John Collier | Diphtheria toxin receptor-binding region |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| JP4469026B2 (ja) | 1996-10-31 | 2010-05-26 | ヒューマン ジノーム サイエンシーズ，インコーポレイテッド | Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| DE60043930D1 (de) | 1999-03-19 | 2010-04-15 | Glaxosmithkline Biolog Sa | Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae |
| WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| US20030035806A1 (en) | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
| ATE396739T1 (de) | 2001-10-01 | 2008-06-15 | Us Health | Entwicklung einer vakzine zur prävention von infektionen mit filovirus bei primaten |
| US6706305B2 (en) | 2001-10-31 | 2004-03-16 | Conagra Foods Inc. | Low glycemic index bread |
| CN105566497A (zh) | 2002-05-10 | 2016-05-11 | 新世纪药品有限公司 | 融合铁蛋白在疫苗和其他方面的应用 |
| JP5525689B2 (ja) | 2004-11-02 | 2014-06-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 過剰増殖性障害を処置するための組成物および方法 |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| US8110196B2 (en) | 2005-04-29 | 2012-02-07 | Polytopas LLC | Methods and compositions for polytopic vaccination |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| CA2665090A1 (en) | 2006-09-22 | 2008-03-27 | Dana-Farber Cancer Institute, Inc. | Methods for treating mica-related disorders |
| US8182809B1 (en) * | 2008-09-08 | 2012-05-22 | University Of Washington | Methods for treating cancer by inhibiting MIC shedding |
| US20120269721A1 (en) | 2009-10-12 | 2012-10-25 | The Regents Of The University Of California | Targeted nanoclusters and methods of their use |
| EP2514718A4 (en) | 2009-12-18 | 2013-09-04 | Kao Corp | METHOD FOR PRODUCING MESOPOROUS SILICONE ARTICLES |
| JP5603063B2 (ja) | 2009-12-21 | 2014-10-08 | 花王株式会社 | 複合シリカ粒子の製造方法 |
| RU2489169C2 (ru) * | 2010-10-12 | 2013-08-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) | Способ лечения онкологических заболеваний |
| KR20140069222A (ko) * | 2011-09-23 | 2014-06-09 | 유니버시티 오브 오슬로 | 교차 제시 수지상 세포를 표적으로 하는 백시바디 |
| ES2619707T3 (es) | 2011-09-30 | 2017-06-26 | Dana-Farber Cancer Institute, Inc. | Péptidos terapéuticos |
| WO2013117647A1 (en) * | 2012-02-07 | 2013-08-15 | Innate Pharma | Mica binding agents |
| PT2838515T (pt) | 2012-04-16 | 2020-02-25 | Harvard College | Composições de sílica mesoporosa para modular respostas imunológicas |
| AU2014228502A1 (en) | 2013-03-15 | 2015-08-20 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| JP6518199B6 (ja) * | 2013-03-15 | 2019-06-12 | ノヴェロジックス・バイオテクノロジー，インコーポレーテッド | Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 |
| AU2015229009B2 (en) * | 2014-03-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring NKG2D pathway function against cancers |
-
2016
- 2016-12-05 MY MYPI2018000849A patent/MY199248A/en unknown
- 2016-12-05 CR CR20180350A patent/CR20180350A/es unknown
- 2016-12-05 AU AU2016362597A patent/AU2016362597C1/en active Active
- 2016-12-05 PE PE2022002801A patent/PE20230495A1/es unknown
- 2016-12-05 PE PE2018001072A patent/PE20181158A1/es unknown
- 2016-12-05 CN CN201680080434.4A patent/CN108770343A/zh active Pending
- 2016-12-05 MX MX2018006785A patent/MX2018006785A/es unknown
- 2016-12-05 SG SG11201804597TA patent/SG11201804597TA/en unknown
- 2016-12-05 KR KR1020187019140A patent/KR20180088458A/ko not_active Ceased
- 2016-12-05 CA CA3005910A patent/CA3005910A1/en active Pending
- 2016-12-05 RU RU2018123307A patent/RU2747296C2/ru active
- 2016-12-05 EA EA201891287A patent/EA201891287A1/ru unknown
- 2016-12-05 CU CU2021000061A patent/CU20210061A7/es unknown
- 2016-12-05 CU CU2018000050A patent/CU24609B1/es unknown
- 2016-12-05 BR BR112018010705A patent/BR112018010705A8/pt active Search and Examination
- 2016-12-05 JP JP2018528691A patent/JP7099956B2/ja active Active
- 2016-12-05 US US15/781,448 patent/US10993971B2/en active Active
- 2016-12-05 CR CR20230116A patent/CR20230116A/es unknown
- 2016-12-05 WO PCT/US2016/064969 patent/WO2017096374A1/en not_active Ceased
- 2016-12-05 TN TNP/2018/000187A patent/TN2018000187A1/en unknown
- 2016-12-05 RU RU2021109510A patent/RU2021109510A/ru unknown
- 2016-12-05 NZ NZ742663A patent/NZ742663A/en unknown
- 2016-12-05 EP EP16816550.4A patent/EP3383426A1/en active Pending
-
2018
- 2018-05-21 IL IL259490A patent/IL259490A/en unknown
- 2018-06-01 PH PH12018501170A patent/PH12018501170A1/en unknown
- 2018-06-01 MX MX2022010194A patent/MX2022010194A/es unknown
- 2018-06-01 CL CL2018001470A patent/CL2018001470A1/es unknown
- 2018-06-27 CO CONC2018/0006642A patent/CO2018006642A2/es unknown
-
2021
- 2021-02-19 US US17/180,183 patent/US20210299186A1/en not_active Abandoned
- 2021-05-13 CL CL2021001256A patent/CL2021001256A1/es unknown
-
2022
- 2022-03-21 AU AU2022201940A patent/AU2022201940B2/en active Active
- 2022-04-14 ZA ZA2022/04223A patent/ZA202204223B/en unknown
- 2022-06-30 JP JP2022105405A patent/JP7564842B2/ja active Active
-
2023
- 2023-10-26 CL CL2023003217A patent/CL2023003217A1/es unknown
-
2024
- 2024-02-19 US US18/581,148 patent/US20250064863A1/en active Pending
- 2024-09-27 JP JP2024167997A patent/JP2024177207A/ja active Pending
-
2025
- 2025-08-08 AU AU2025213685A patent/AU2025213685A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003217A1 (es) | Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer | |
| MX389560B (es) | Enfoque de inmunoterapias de combinación para el tratamiento del cancer. | |
| CL2018001358A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
| MX389707B (es) | Neurotoxinas quimericas. | |
| UY36701A (es) | Tratamiento contra el cáncer por manipulación de la microflora comensal | |
| MX369921B (es) | Tratamiento de la hgna y ehna. | |
| MX393612B (es) | Vacuna contra viruela para tratamiento del cancer. | |
| MX2016017108A (es) | Composiciones y metodos para el cuidado personal. | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
| EA201692552A1 (ru) | МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp | |
| MX2017006019A (es) | Apilimod para uso en el tratamiento de melanoma. | |
| EA201890868A1 (ru) | Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей | |
| JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
| BR112016019389A8 (pt) | Vacina, e, peptídeo | |
| PH12016501838A1 (en) | Compounds and their methods of use | |
| BR112019004102A2 (pt) | imunoterapia para poliomavírus | |
| AU355238S (en) | Dental appliance | |
| MX2016010967A (es) | Nuevas composiciones para tratar lesiones neuronales mecanicas. | |
| MX2017014893A (es) | Composicion herbal para el tratamiento del dolor de espalda. | |
| HK1262082A1 (en) | Vaccination with mica/b alpha 3 domain for the treatment of cancer |